The MRP 8/14 ELISA is for Research Use Only.
Measurement of MRP 8/14 has been reported to be a marker of minimal residual inflammation, which is not detected by other diagnostic tests. MRP 8/14 has been proposed as a potentially versatile and early marker of inflammation ,reported to be involved in acute coronary syndromes, rheumatoid arthritis, sepsis, kidney allograft rejection and irritable bowel disease. ALPCO's (Buhlmann) MRP 8/14 ELISA is available in the US for Research Use Only.
Acute Coronary Syndromes (ACS)
Levels of MRP 8/14 have been reported to be elevated in ACS at the site of coronary occlusion and in the systemic circulation, indicating its involvement in this process. In a screening approach among healthy individuals, it has also been reported that increasing plasma concentrations of MRP 8/14 can predict the risk of future cardiovascular events. This makes this heterodimer a prime candidate for the early and sensitive stratification of patients with chest pain. (1)
Rheumatoid Arthritis (RA)
In vitro interaction of monocytes with activated endothelial cells it reported to induce secretion of MRP 8/14 via elevation of intracellular calcium. Serum concentration of MRP 8/14 correlates with the state of disease activity or remission in juvenile rheumatoid arthritis (2), are proposed to be a useful marker for rheumatoid arthritis; and also correlates well with concentrations measured in synovial fluid, where it might have utility in monitoring local inflammation. (3)
Sepsis
The outcome of sepsis is poor and it remains a major challenge in the care of critically ill patients. Circulating MRP 8/14 levels are elevated in subjects with severe sepsis, irrespective of the primary source of infection; MRP 8/14 plasma levels are elevated in patients with sepsis and in healthy humans injected with LPS. MRP 8/14 has been reported to provide a means of measuring the severity of sepsis occurring in response to many different types of infections. (4)
Kidney Allograft Rejection
In renal allograft patients who experience acute rejection within the first four weeks serum levels of MRP 8/14 are reported to be significantly increased during the first two weeks after transplantation. In addition, serum levels of MRP 8/14 were observed to be significantly reduced following intravenous methylprednisolone antirejection therapy. These results suggest that monitoring MRP 8/14 levels can potentially provide clinicians with useful information regarding factors increasing the risk of rejection and the efficacy of immunosuppressive drug treatment to prevent it. (5)
(1) L.A. Altwegg et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. European Heart Journal (2007) 28, 941-948.
(2) M. Frosch et al. Myeloid-related proteins 8 and 14 are specifically secreted during interactions of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis & Rheumatism (2000) 43, 628-637.
(3) M. Othman. Correlation of MRP8/MRP14 and S100A12 with disease activity in rheumatoid and psoriatic arthritis. Journal of American Science (2011) 7, 983-994.
(4) M.A.D. van Zoelen et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. American Journal of Respiratory & Critical Care Medicine (2009) 180, 1098-1106.
(5) K. Burkhardt et al. An increase in myeloid-related protein serum levels precedes acute renal allograft rejection. Journal of the American Society of Nephrology (2001) 12, 1947-1957.
For more information on the MRP 8/14 ELISA, call 800-592-5726.